GO:0009188 ribonucleoside diphosphate biosynthetic process: Nucleotide Metabolism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009188 describes the biosynthesis of ribonucleoside diphosphates, essential precursors for RNA and DNA synthesis [1,4].
• Ribonucleotide reductase (RRM1/RRM2) is the rate-limiting enzyme that converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates, a critical step for DNA replication and repair [1,4].
• Dysregulation of this pathway is linked to cancer, as RRM1 overexpression contributes to gemcitabine resistance and tumor progression [1,4].
• The pathway intersects with redox biology and purinergic signaling, influencing cellular stress responses.
• Emerging evidence implicates non-canonical ADP-ribosylation and PARylation in regulating nucleotide metabolism and DNA modifications [7,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of this pathway in disease contexts [1,6].
Description
Ribonucleoside diphosphate biosynthetic process (GO:0009188) encompasses the enzymatic steps that produce ribonucleoside diphosphates, which are fundamental building blocks for RNA and, after reduction, DNA [1,4]. These molecules serve as substrates for RNA polymerases and are central to energy metabolism and signaling. The pathway is tightly regulated to meet cellular demands for nucleotides during proliferation, DNA repair, and stress responses. Dysregulation of ribonucleoside diphosphate biosynthesis is implicated in cancer, where increased nucleotide pools support rapid cell division and confer resistance to nucleoside analog drugs such as gemcitabine [1,4]. Moreover, the pathway intersects with redox homeostasis and purinergic signaling, highlighting its broader physiological significance. Understanding the molecular players and regulatory mechanisms is essential for developing targeted therapies and for interpreting metabolic reprogramming in disease [1,4]. Recent advances in CRISPR gene editing have enabled precise manipulation of genes involved in this pathway, facilitating functional studies and drug discovery [1,6]. This article provides a comprehensive overview of GO:0009188, covering its definition, key genes, regulatory mechanisms, disease associations, and research methodologies.
ribonucleoside diphosphate biosynthetic process At A Glance
| GO ID | GO:0009188 |
|---|---|
| GO term | ribonucleoside diphosphate biosynthetic process |
| Ontology | biological_process |
| Synonym | ribonucleoside diphosphate anabolism, ribonucleoside diphosphate biosynthesis, ribonucleoside diphosphate formation, ribonucleoside diphosphate synthesis |
| Major function | Production of ribonucleoside diphosphates for RNA synthesis and as precursors for DNA synthesis |
| Key enzymes | Ribonucleotide reductase (RRM1, RRM2), NME1, NME2, and other kinases |
| Pathway context | Nucleotide metabolism, purine and pyrimidine biosynthesis |
| Disease relevance | Cancer, viral infections, and metabolic disorders |
What Is GO:0009188?
GO:0009188, ribonucleoside diphosphate biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of a ribonucleoside diphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with diphosphate on the sugar. This process includes de novo synthesis and salvage pathways that generate ribonucleoside diphosphates such as ADP, GDP, CDP, and UDP, which are essential for RNA synthesis and as precursors for deoxyribonucleotides [1,4].
Why Is ribonucleoside diphosphate biosynthetic process Important in Cell Biology?
The ribonucleoside diphosphate biosynthetic process is fundamental to all living cells because it supplies the precursors for RNA and DNA synthesis. Without adequate levels of ribonucleoside diphosphates, cells cannot proliferate or repair DNA damage, leading to genomic instability and cell death [1,4]. This pathway is also a target for anticancer and antiviral therapies, as inhibiting key enzymes like ribonucleotide reductase can halt tumor growth and viral replication. Furthermore, the pathway is intertwined with cellular redox balance and signaling cascades, making it a central node in metabolic regulation.
• Provides essential precursors for RNA synthesis and DNA replication [1,4].
• Rate-limiting enzyme RRM1 is a validated target for cancer therapy [1,4].
• Dysregulation contributes to gemcitabine resistance in lung adenocarcinoma.
• Links to redox biology through purinergic signaling and oxidative stress responses.
• Involved in non-canonical ADP-ribosylation and DNA modifications [7,8].
• NME1 and NME2 are implicated in metastasis suppression and cancer progression.
• Targeted by nucleoside analog drugs used in chemotherapy and antiviral treatment.
• Metabolic reprogramming in cancer often upregulates this pathway [1,4].
• CRISPR screens can identify novel regulators of nucleotide metabolism [1,6].
• Potential biomarker for predicting drug response and patient prognosis.
What Happens During ribonucleoside diphosphate biosynthetic process?
De Novo Purine Biosynthesis
In simple terms: The cell builds purine rings from scratch using simple molecules like amino acids and CO2.
De novo purine biosynthesis generates inosine monophosphate (IMP), which is subsequently converted to adenosine and guanosine diphosphates (ADP and GDP) through a series of enzymatic steps [1,4]. This pathway is energy-intensive and tightly regulated by feedback inhibition. Key enzymes include phosphoribosyl pyrophosphate (PRPP) synthetase and IMP dehydrogenase. The resulting ribonucleoside diphosphates serve as substrates for RNA synthesis and can be further phosphorylated to triphosphates.
De Novo Pyrimidine Biosynthesis
In simple terms: The cell assembles pyrimidine rings and attaches them to ribose to form UDP and CDP.
Pyrimidine biosynthesis begins with the formation of carbamoyl phosphate, which is converted to uridine monophosphate (UMP) and then to UDP and CDP [1,4]. This pathway is regulated by carbamoyl phosphate synthetase II and aspartate transcarbamoylase. The generated ribonucleoside diphosphates are essential for RNA synthesis and can be reduced to deoxyribonucleotides for DNA replication.
Salvage Pathways
In simple terms: The cell recycles nucleobases from degraded RNA or DNA to make new nucleotides.
Salvage pathways recover free nucleobases and nucleosides from nucleic acid turnover and convert them into ribonucleoside diphosphates via kinases such as adenosine kinase and uridine kinase [1,4]. These pathways are particularly important in tissues with high nucleotide demand, such as the bone marrow and intestinal epithelium. Deficiencies in salvage enzymes can lead to immunodeficiency and neurological disorders.
Reduction to Deoxyribonucleotides
In simple terms: Ribonucleoside diphosphates are converted to deoxyribonucleotides, the building blocks of DNA.
Ribonucleotide reductase (RRM1/RRM2) catalyzes the reduction of ribonucleoside diphosphates to their deoxy counterparts, a critical step for DNA synthesis and repair [1,4]. This enzyme is highly regulated by allosteric effectors and is a target for anticancer drugs like gemcitabine and hydroxyurea. Inhibition of RRM1 sensitizes lung adenocarcinoma to decitabine treatment.
Key Genes Involved in GO:0009188 ribonucleoside diphosphate biosynthetic process
The following genes encode enzymes and regulatory proteins directly involved in the ribonucleoside diphosphate biosynthetic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Ribonucleotide reductase subunit M1, catalytic subunit | Target for gemcitabine; biomarker for drug resistance [1,4] |
| RRM2 | Ribonucleotide reductase subunit M2, regulatory subunit | Cell cycle-regulated; target for cancer therapy |
| NME1 | Nucleoside diphosphate kinase A, transfers phosphate groups | Metastasis suppressor; regulated by YTHDF2 in gallbladder cancer |
| NME2 | Nucleoside diphosphate kinase B | Involved in nucleotide metabolism and cancer progression |
| ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 | Regulates nucleotide signaling; target for cancer immunotherapy |
| ADK | Adenosine kinase, salvage pathway | Regulates adenosine levels; linked to redox biology |
| UMPK | Uridine monophosphate kinase | Phosphorylates UMP to UDP in pyrimidine synthesis |
| CTPS1 | CTP synthase 1 | Converts UTP to CTP; involved in pyrimidine biosynthesis |
| GUK1 | Guanylate kinase 1 | Phosphorylates GMP to GDP |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase 1 | Rate-limiting enzyme in purine biosynthesis |
| IMPDH1 | Inosine monophosphate dehydrogenase 1 | Converts IMP to XMP in guanine synthesis |
| IMPDH2 | Inosine monophosphate dehydrogenase 2 | Regulates guanine nucleotide pools |
| ATIC | AICAR transformylase/IMP cyclohydrolase | Bifunctional enzyme in purine biosynthesis |
| GART | Glycinamide ribonucleotide transformylase | Purine biosynthesis enzyme |
| PAICS | Phosphoribosylaminoimidazole carboxylase | Purine biosynthesis enzyme |
| CAD | Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase | Multifunctional enzyme in pyrimidine biosynthesis |
| DHODH | Dihydroorotate dehydrogenase | Mitochondrial enzyme in pyrimidine synthesis |
| UMPS | Uridine monophosphate synthetase | Bifunctional enzyme in pyrimidine synthesis |
How Is ribonucleoside diphosphate biosynthetic process Regulated?
The ribonucleoside diphosphate biosynthetic process is regulated at multiple levels. Ribonucleotide reductase (RRM1/RRM2) is controlled by cell cycle-dependent transcription, allosteric feedback by dATP and ATP, and degradation of RRM2 in S phase [1,4]. Purine and pyrimidine biosynthesis are feedback-inhibited by end products and activated by PRPP availability. Additionally, purinergic signaling and redox status modulate enzyme activities, linking nucleotide metabolism to cellular stress responses. Non-canonical ADP-ribosylation and PARylation can also influence nucleotide pools and DNA modifications [7,8].
ribonucleoside diphosphate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RRM1 | Lung adenocarcinoma, gemcitabine resistance | Knockout and overexpression in A549 cells |
| NME1 | Gallbladder cancer progression | Knockdown and overexpression in GBC cell lines |
| ENPP1 | Cancer immunotherapy resistance | Knockout in melanoma models |
| ADK | Redox imbalance, neurological disorders | Point mutation knock-in in mice |
| RRM2 | Cancer cell proliferation | Inducible knockdown in HeLa cells |
Cancer
Dysregulated ribonucleoside diphosphate biosynthesis supports the high proliferative rate of cancer cells. RRM1 overexpression is associated with gemcitabine resistance in lung adenocarcinoma, and its inhibition sensitizes tumors to decitabine. NME1 and NME2 are implicated in metastasis suppression and are regulated by YTHDF2 in gallbladder cancer. Targeting ENPP1 enhances cancer immunotherapy by modulating nucleotide signaling.
Metabolic and Redox Disorders
Purinergic signaling, which intersects with ribonucleoside diphosphate metabolism, modulates redox biology and oxidative stress responses. Metal/ADP complexes can promote phosphorylation of ribonucleotides, suggesting a role in pathological calcification and metabolic disorders.
DNA Damage and Epigenetics
Non-canonical ADP-ribosylation and PARylation are reversible DNA modifications that influence chromatin structure and DNA repair, linking nucleotide metabolism to epigenetic regulation [7,8]. N1-adenosine PARylation is a reversible DNA modification in mammals.
From ribonucleoside diphosphate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does RRM1 loss sensitize to decitabine? | RRM1 knockout in lung adenocarcinoma cell lines |
| How does NME1 mutation affect metastasis? | Point mutation knock-in in gallbladder cancer cells |
| Can ENPP1 inhibition boost immunotherapy? | ENPP1 knockout in mouse tumor models |
| What is the role of ADK in redox regulation? | ADK overexpression and knockout in neuronal cells |
| How does RRM2 degradation affect cell cycle? | Tagged knock-in of RRM2 for live-cell imaging |
| Does PARylation regulate nucleotide pools? | Knock-in of PARP1 mutants in HEK293T cells [7,8] |
How to Study the ribonucleoside diphosphate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify pathway regulators |
| CRISPR knockout screen | Gene essentiality | Discover vulnerabilities in cancer cells |
| Metabolomics | Nucleotide pool sizes | Quantify ribonucleoside diphosphates |
| Enzymatic assay | Ribonucleotide reductase activity | Screen for inhibitors |
| Live-cell imaging | Protein localization and dynamics | Study RRM2 degradation |
| Proteomics | Protein interactions and modifications | Identify ADP-ribosylation targets |
| Isotope tracing | Metabolic flux | Measure de novo synthesis |
| CRISPR interference | Gene knockdown | Study dose-dependent effects |
Genomic and Transcriptomic Profiling
RNA-seq and CRISPR screens can identify genes and pathways regulating ribonucleoside diphosphate biosynthesis. For example, CRISPR knockout screens have revealed RRM1 as a key vulnerability in lung adenocarcinoma. Transcriptomic analysis of NME1 and NME2 in gallbladder cancer highlights their regulation by YTHDF2.
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics quantifies ribonucleoside diphosphate levels and isotope tracing reveals flux through de novo and salvage pathways. This approach can assess the impact of enzyme inhibitors or genetic perturbations.
Enzymatic Assays
In vitro enzymatic assays measure ribonucleotide reductase activity using radiolabeled substrates or coupled reactions. These assays are used to screen for inhibitors and to characterize mutant enzymes.
Imaging and Proteomics
Fluorescent tagging of enzymes like RRM2 enables live-cell imaging of subcellular localization and dynamics. Proteomics can identify post-translational modifications such as ADP-ribosylation that regulate nucleotide metabolism [7,8].
How CRISPR Can Be Used to Study GO:0009188 ribonucleoside diphosphate biosynthetic process
Knockout
CRISPR knockout of RRM1 in lung adenocarcinoma cells sensitizes them to decitabine, demonstrating the therapeutic potential of targeting this pathway. Knockout of ENPP1 in melanoma models enhances immunotherapy responses.
Point Mutation
Point mutations in NME1 can be introduced to study loss of metastasis suppressor function in gallbladder cancer. Similarly, mutations in ADK can model redox-related disorders.
Knock-in
Knock-in of tagged RRM2 allows live-cell imaging of its degradation and localization. Knock-in of PARP1 mutants can elucidate the role of PARylation in DNA modification [7,8].
Overexpression
Overexpression of RRM1 confers gemcitabine resistance in cancer cells, providing a model to study drug resistance mechanisms. Overexpression of NME1 suppresses metastasis in gallbladder cancer.
How EDITGENE Supports ribonucleoside diphosphate biosynthetic process Research
Researchers studying ribonucleoside diphosphate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in disease or drug response. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for ribonucleoside diphosphate biosynthetic process research.
Frequently Asked Questions About ribonucleoside diphosphate biosynthetic process
What is GO:0009188?
GO:0009188 is the Gene Ontology term for ribonucleoside diphosphate biosynthetic process, the set of chemical reactions that produce ribonucleoside diphosphates like ADP, GDP, CDP, and UDP [1,4].
What genes are involved in ribonucleoside diphosphate biosynthetic process?
Key genes include RRM1, RRM2, NME1, NME2, ENPP1, ADK, and enzymes of purine and pyrimidine biosynthesis such as IMPDH1, CTPS1, and CAD [1,4,5,6].
Why is ribonucleoside diphosphate biosynthesis important for cancer?
Cancer cells require high nucleotide levels for rapid proliferation; targeting this pathway, e.g., RRM1 inhibition, can sensitize tumors to chemotherapy [1,4].
How is ribonucleoside diphosphate biosynthesis regulated?
It is regulated by feedback inhibition, cell cycle-dependent expression of RRM1/RRM2, and allosteric control by nucleotides [1,4].
What diseases are associated with defects in this pathway?
Dysregulation is linked to cancer, metabolic disorders, and redox imbalance; NME1 mutations are associated with gallbladder cancer [1,2,6].
What methods are used to study ribonucleoside diphosphate biosynthesis?
Common methods include CRISPR knockout screens, metabolomics, enzymatic assays, RNA-seq, and live-cell imaging [1,4,6].
Can CRISPR be used to model ribonucleoside diphosphate biosynthetic process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study gene function in this pathway [1,6].
What is the role of RRM1 in gemcitabine resistance?
RRM1 overexpression reduces gemcitabine efficacy; its inhibition sensitizes lung adenocarcinoma to decitabine.
How does NME1 relate to cancer metastasis?
NME1 acts as a metastasis suppressor, and its downregulation by YTHDF2 promotes gallbladder cancer progression.
What is the connection between purinergic signaling and redox biology?
Purinergic signaling modulates redox homeostasis, and enzymes like ADK influence oxidative stress responses.
Conclusion
The ribonucleoside diphosphate biosynthetic process (GO:0009188) is a central metabolic pathway that supplies the building blocks for RNA and DNA. Its dysregulation is implicated in cancer, metabolic disorders, and redox imbalance, making it a prime target for therapeutic intervention [1,4]. Advances in CRISPR gene editing and metabolomics have accelerated our understanding of this pathway, revealing new vulnerabilities and biomarkers [1,6]. EDITGENE offers a comprehensive suite of CRISPR services, including knockout, point mutation, knock-in, overexpression, and library screening, to support research on this critical pathway. By leveraging these tools, researchers can elucidate the molecular mechanisms of ribonucleoside diphosphate biosynthesis and translate findings into novel therapies.
References
- 1. Jiang N et al.. 2026. RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.. Cell Death Dis 17(1) PMID: 41748545
- 2. Savio LEB et al.. 2021. Purinergic signaling in the modulation of redox biology.. Redox Biol 47:102137 PMID: 34563872
- 3. Werner E et al.. 2023. Metal/ADP Complexes Promote Phosphorylation of Ribonucleotides.. J Am Chem Soc 145(39):21630-21637 PMID: 37750669
- 4. Huff SE et al.. 2022. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.. Biomolecules 12(6) PMID: 35740940
- 5. Huang R et al.. 2024. Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone.. Biochem Pharmacol 220:116006 PMID: 38142838
- 6. Zhu EL et al.. 2026. N6-methyladenosine reader YTHDF2 facilitates malignant progression of gallbladder cancer by suppressing NME1 expression.. Cancer Lett 659:218754 PMID: 42498073
- 7. Schuller M et al.. 2022. Beyond protein modification: the rise of non-canonical ADP-ribosylation.. Biochem J 479(4):463-477 PMID: 35175282
- 8. Musheev MU et al.. 2022. Mammalian N1-adenosine PARylation is a reversible DNA modification.. Nat Commun 13(1):6138 PMID: 36253381
